Gap Analysts Boost Their Forecasts Following Upbeat Results

The Gap, Inc. (NYSE:GPS) posted better-than-expected results for its first quarter on Thursday. Gap reported quarterly sales of…

The Gap, Inc. (NYSE:GPS) posted better-than-expected results for its first quarter on Thursday.

Gap reported quarterly sales of $3.39 billion which beat the analyst consensus estimate of $3.29 billion by 2.98 percent. The company reported quarterly earnings of 41 cents per share which beat the analyst consensus estimate of 14 cents, according to data from Benzinga Pro.

Comparable sales were up 3% year-over-year. Store sales were up 3%, while online sales jumped 5%. Merchandise margin increased 340 basis points compared to the prior year.

“Gap Inc. delivered a strong quarter that exceeded expectations across key metrics. We gained market share for the 5th consecutive quarter with positive comparable sales at all brands, demonstrating improved relevance with our customers as we execute against our brand reinvigoration playbook,” said Richard Dickson, president and CEO of Gap.

Gap expects second-quarter net sales to increase in the low-single-digit range on a year-over-year basis. Gap also raised its full-year guidance to reflect higher net sales and meaningfully higher operating income growth compared to the company’s prior expectations.

Gap shares gained 4% to close at $22.52 on Thursday.

These analysts made changes to their price targets on Gap after the company reported quarterly results.

  • Baird raised the price target on Gap from $23 to $28. Baird analyst Mark Altschwager maintained a Neutral rating.
  • Telsey Advisory Group increased Gap price target from $22 to $29. Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating on the stock.
  • Morgan Stanley boosted the price target on Gap from $20 to $27. Morgan Stanley analyst Alex Straton maintained an Equal-Weight rating.

Read More: How To Earn $500 A Month From Pfizer Stock

Total
0
Shares
Related Posts
Read More

Acrivon Therapeutics Presents Data At AACR Annual Meeting Highlighting Capabilities Of Acrivon Predictive Precision Proteomics For The Discovery Of ACR-2316, A Novel, Selective WEE1/PKMYT1 Inhibitor, And The Identification Of Actionable Resistance Mech…

ACR-2316, which was internally discovered using biological SAR enabled by AP3 to overcome limitations of benchmark clinical WEE1 and PKMYT1 inhibitors, demonstrates potent anticancer activity in preclinical studies and

ACRV